RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Alimera Sciences Stock

Alimera Sciences Stocks 2024

Alimera Sciences Stocks

25.56 M

Ticker

ALIM

ISIN

US0162592028

WKN

A2PVHE

In 2024, Alimera Sciences had 25.56 M outstanding stocks, a 0% change from the 25.56 M stocks in the previous year.

The Alimera Sciences Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e25.56
2028e25.56
2027e25.56
2026e25.56
2025e25.56
2024e25.56
202325.56
20227
20216.6
20205.12
20194.77
20185.92
201766.99
201652.8
201544.45
201440.4
201331.58
201231.46
201131.36
201022.17
20091.52
20081.51
20071.5
20064.89
20054.89
20044.89

Alimera Sciences shares outstanding

The number of shares was Alimera Sciences in 2023 — This indicates how many shares 25.562 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alimera Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alimera Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alimera Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alimera Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Alimera Sciences Aktienanalyse

What does Alimera Sciences do?

Alimera Sciences Inc. is a leading global company specializing in the development of pharmaceutical products for eye diseases. The company was founded in 2003 in Atlanta, Georgia, USA and has since made remarkable progress in developing innovative clinical solutions. Business model: Alimera Sciences Inc. strives to utilize the latest technologies and methods in ophthalmology to improve the quality of life for patients with eye diseases. The company works closely with leading research institutions to incorporate the latest scientific findings into its product development. Alimera Sciences has a wide range of research areas to develop innovative solutions for conditions such as diabetes-related macular degeneration, retinopathy, uveitis, and other eye diseases. The company also places great value on collaboration with the medical community and actively advocates for the improvement of patient care and the education of eye experts. Products: Alimera Sciences' products are specialized in the treatment of eye diseases and utilize various technologies to improve patients' quality of life. The flagship product of Alimera Sciences is Iluvien, an intravitreal implant for the treatment of chronic diabetic macular edema (DME). Iluvien is the only commercially available DME implant and offers a unique treatment option for patients who do not respond to standard treatments. In addition to Iluvien, Alimera Sciences also manufactures a range of other products, including Ozurdex, a steroid-containing intravitreal implant for the treatment of retinopathy and uveitis. Alimera Sciences also has an extensive portfolio of investigational drugs, many of which are in various stages of clinical development. History: Alimera Sciences was founded in 2003 by Daniel C. Myers and David R. Holland in Atlanta, Georgia. The company originally specialized in developing drugs for the treatment of lung diseases, but over the years, its focus shifted to ophthalmology. In 2011, the company received FDA approval for Iluvien, which was a significant milestone in the history of Alimera Sciences. Since then, the company has continuously expanded its presence in ophthalmology by increasing its research and development efforts and forming partnerships with key medical organizations and institutions. Today, Alimera Sciences is a leading provider of pharmaceutical solutions for eye diseases, focusing on the development of drugs to improve patients' quality of life and enhance medical care. Conclusion: Overall, Alimera Sciences is an innovative company specializing in the development of drugs for the treatment of eye diseases. In its 18 years of existence, the company has achieved an impressive success story and continues its efforts to attain a leading position in the ophthalmic industry. With insights and experience in medical history and the knowledge of important medical professionals, the company is prepared to continuously meet the medical needs and expectations of patients with eye diseases. Alimera Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Alimera Sciences's Shares Outstanding

Alimera Sciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Alimera Sciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Alimera Sciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Alimera Sciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Alimera Sciences stock

How many stocks are there of Alimera Sciences?

The current number of stocks of Alimera Sciences is 25.56 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Alimera Sciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Alimera Sciences evolved in recent years?

The number of shares of Alimera Sciences has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Alimera Sciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Alimera Sciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Alimera Sciences pay?

Over the past 12 months, Alimera Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alimera Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Alimera Sciences?

The current dividend yield of Alimera Sciences is .

When does Alimera Sciences pay dividends?

Alimera Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alimera Sciences?

Alimera Sciences paid dividends every year for the past 0 years.

What is the dividend of Alimera Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alimera Sciences located?

Alimera Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alimera Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alimera Sciences from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Alimera Sciences pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Alimera Sciences in the year 2023?

In the year 2023, Alimera Sciences distributed 0 USD as dividends.

In which currency does Alimera Sciences pay out the dividend?

The dividends of Alimera Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Alimera Sciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Alimera Sciences

Our stock analysis for Alimera Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alimera Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.